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Abstract
Background: Cell lines are very useful for both clinical and basic research. The establishment of ovarian, malignant
tumor cell lines with aggressive histology is especially important. We describe the establishment and
characterization of a new human clear cell carcinoma cell line of the ovary.
Results: The cell line HCH-1 was established from an ovarian tumor from a 67-year-old woman. This cell line has
grown well for 230 months and has been subcultured more than 50 times. Monolayer cultured cells are polygonal
in shape, showing a pavement-like arrangement and a tendency to pile up without contact inhibition. It exhibits a
human karyotype with a modal chromosomal number in the hypodiploid range. The cells could be transplanted
into the subcutis of SCID mice and produced tumors resembling the original tumor. HCH-1 cells produced CA125
and CA19-9, also identified immunohistochemically in both the original tumor and the heterotransplanted tumors.
The cells were sensitive to actinomycin D, carboplatin, cisplatin and mitomycin C, drugs commonly used in the
treatment of gynecological cancers. Variant was not found in hotspot of the 50 most commonly reported
oncogenes and tumor suppressor genes. Only 12 ovarian clear cell carcinoma cell lines and their characteristics
have thus far been reported in the literature. HCH-1 is the first ovarian clear cell carcinoma cell line reported in
which the chromosome number is in the hypodiploid range and only the second cell line in which CA125 and
CA19-9 are expressed.
Conclusions: Since it is impossible to establish a cell line from the malignant tumor of each patient, the cell line
that we established, characterized and report in this paper may be very useful in basic research on ovarian cancer.
We have much to learn about the pathogenesis of clear cell carcinoma and this extra line of enquiry may lead us
to a better understanding of how to treat and cure this serious disease.
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Background
Clear cell carcinoma of the ovary is an epithelial ovarian
cancer that has frequent concurrence with endometriotic
lesions [1]. The prognosis is worse than that of any other
epithelial ovarian cancer because of its poor chemosensi-
tivity [2]. Previous molecular studies have indicated that
mutation in PIK3CA [3], ARID1A [4], and genomic
amplification of chr20q13.2 [5] are the most common
molecular genetic alterations identified in ovarian clear
cell carcinoma. But oncogenesis of ovarian clear cell
carcinoma has not been elucidated still now. Therefore,
it was considered important to develop an ovarian clear
cell carcinoma cell line for clinical and basic research on
this disease. We describe here the establishment and
characterization of a new human clear cell carcinoma
cell line (HCH-1) that expresses CA 125 and CA 19–9.
Methods
Materials
We performed an abdominal simple total hysterectomy,
bilateral salpingo-oophorectomy, and omentectomy on a
67-year-old woman with ovarian cancer FIGO stage IIc
19 years ago. The right ovarian tumor was cystic with
some parts of solid lesions (Fig. 1). The histology was
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clear cell carcinoma of the ovary. Preoperative serum
tumor markers were CA 125; 340.9 U/ml (normal level
<35 U/ml), CA 19–9; 75.4 U/ml (<37 U/ml), α-feto-
protein (AFP); 8.2 ng/ml (<20 ng/ml), carcinoembryonic
antigen (CEA); 1.3 ng/ml (<5.0 ng/ml), and squamous
cell carcinoma (SCC) antigen; 0.6 ng/ml (<1.5 ng/ml).
The patient was treated with intraperitoneal 100 mg cis-
platin and 400 mg etoposide twice, and intravenous
450 mg carboplatin, 60 mg pirarubicin hydrochloride,
400 mg cyclophosphamide four times. However her clin-
ical condition deteriorated progressively because of the
brain metastasis with increasing CA 125. Although the
metastatic tumor was resected by surgery, showing
adenocarcinoma, she died 23 months after the first
surgery. Unfortunately we had not an opportunity to
culture the metastatic tumor. The patient gave written
informed consent before surgery according to institu-
tional guideline.
Culture techniques and culture media
The material from the ovarian tumor was finely minced
with a pair of sharp blades in a dish including serum-
free Ham’s F-12 medium (Flow Laboratories Inc.,
McLean, VA, USA), stirred slowly with a magnetic stirrer
in a 0.25 % trypsin solution (Flow Laboratories Inc.),
centrifuged at 70 g for 5 min and placed in culture
medium at 37 °C in humidified 5 % CO2 and 95 % air.
Cells were cultured in Ham’s F-12 medium plus 20 %
precolostrum newborn calf serum (Mitsubishi Chemical
Industries Ltd., Tokyo, Japan) with kanamycin. Then
subcultures were made with 0.1 % trypsin and 0.02 %
ethylenediamine-tetraacetic acid (EDTA) solution every
4 weeks. Three months after primary culture the
concentration of precolostrum newborn calf serum in
the culture medium was reduced from 20 to 10 %.
Morphology of the culture material and cultured cells
Living cells grown in culture flasks were examined using a
phase contrast microscope. For light microscopy, the ori-
ginal tumor was fixed in 10 % formalin, embedded in paraf-
fin, and 4 μm-sections were stained with hematoxylin-eosin
(HE). Monolayer cells cultured on slides were fixed in 90 %
ethanol and stained by Papanicolaou’s procedure [6].
Growth characteristics
Cell characteristics were examined chronologically. Sus-
pensions of 1×105 cells each were placed on 35 mm
plastic dishes. Cells were incubated for 15 days, and cells
in two dishes were counted by an automatic cell counter
(Coulter CounterR, Coulter Electronics, Luton, England)
every other day. The population doubling time and sat-
uration density were calculated from the growth curve.
For studies of plating efficiency, 1×102 and 2×102 single-
suspension cells were placed onto five-60 mm plastic
dishes each and cultured for 14 days. Plating efficiency
was determined by the ratio of the number of colonies
(more than 10 cells) to the total number of inoculated
cells. For the mitotic index, the monolayer cells were
cultured for 5 days and treated with 1×10−7 M colcemid
(Demecolcine Solution, Wako Pure Chemical Industries,
Osaka, Japan) for 4 h, placed in a 0.2 % KCl solution for
15 min, and then fixed step-by-step in a methanol:acetic
acid solution (3:1). After air-drying, the cells were
stained with Giemsa and the mitoses in 1000 cells were
counted.
Chromosome analysis
Histograms of chromosome number distribution were
determined on 50 metaphase plates. Their karyotypes
were analyzed in 9 cells in accordance with the Inter-
national System for Human Cytogenetic Nomenclature
(ISCN 1995).
Heterotransplantation
Ten million cells (passage 10) were inoculated subcuta-
neously into the backs of 6-week-old SCID mice (SCID/
Os; Shionogi, Osaka, Japan). When the tumors had
grown to 5–10 mm in diameter after 4 weeks, they were
removed and processed for morphological examinations.
For light microscopy, the excised tumors were fixed in
10 % formalin, embedded in paraffin, and stained with
HE. For electron microscopy, the original tumor was
fixed by immersion in a mixture of 1.25 % glutaralde-
hyde and 1 % paraformaldehyde buffered with phosphate
saline, pH 7.4, at 4 °C for 3 h. After washing with phos-
phate buffered saline (PBS), the tumor was postfixed
with 1 % osmium tetroxide at 4 °C for 1 h. The tumor
Fig. 1 Macroscopic appearance of the original tumor. The right
ovarian tumor was cystic with some parts of solid lesions. (bar = 5 cm)
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was then washed in PBS, dehydrated in graded concen-
trations of ethanol, and embedded in Epon 812. Sections
0.5 μm thick were cut with a 6000 ultramicrotome
(Sorvall, Du Pont, CT, USA) and stained with toluidine
blue. Ultrathin sections exhibiting a light gold interfer-
ence color were cut from appropriate areas chosen from
the toluidine blue stained sections, double stained with
uranyl acetate and lead citrate, and observed under a
JEM-100SX electron microscope (JEOL, Tokyo, Japan)
at 80 kV [7].
Tumor markers
Culture medium in which 2×106 cells/5 ml were cultured
for 7 days was examined for AFP, CA 125, CA 19–9, CEA,
human chorionic gonadotropin (HCG), SCC antigen, and
tissue polypeptide antigen (TPA) by radioimmunoassay or
chemiluminescent immunoassay.
Immunohistochemical stainings
The deparaffinized sections of the original tumor and
heterotransplanted tumor on glass slides were stained
immunohistochemically using the universal Immuno-
enzyme Polymer (UIP) method (HISTOFINE simple
stain MAX PO; Nichirei Bioscience Inc., Tokyo, Japan).
They were immersed in 0.03 % hydrogen peroxidase and
absolute methanol to block endogenous peroxidase. The
samples were then washed with phosphate buffered sa-
line and heated in a microwave oven for 10 min at a
power of 700 W. After cooling, the slides were incubated
with a primary antibody at 4 °C for 12 h and then added
and reacted with Histfine Simple stain MAX PO at room
temperature for 30 min, followed by diaminobenzidine
(DAB) for sections for 5–10 min. Antibodies used as
tumor markers were CA 125 (DAKO, Glostrup,
Denmark), CA 19–9 (DAKO) and, as hormone receptor
markers, were anti-human estrogen receptor α (Nichirei)
and anti-human progesterone receptor (Nichirei). Hep-
atocyte factor-1β (HNF-1β) [8] (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA, USA) and Annexin IV [9]
(Santa Cruz Biotech) which commonly express in ovar-
ian clear cell carcinoma were also used.
Chemosensitivity assays
A comparison was made between the effects of actinomy-
cin D (ACD, MSD KK, Tokyo, Japan), doxorubicin (ADM,
Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan), 5-fluorouracil
(5-FU, Kyowa Hakko Kirin Co.), mitomycin C (MMC,
Kyowa Hakko Kirin Co.), bleomycin (BLM, Nippon Kayaku
Co., Ltd., Tokyo, Japan), vinblastine (VLB, Nippon Kayaku
Co.), vincristine (VCR, Nippon Kayaku Co.), carboplatin
(CBDCA, Bristol-Myers K.K., Tokyo, Japan), cisplatin
(CDDP, Bristol-Myers), etoposide (VP-16, Bristol-Myers),
paclitaxel (PTX, Bristol-Myers) [10], 4-hydroperoxy-
cyclophosphamide (CPA, Shionogi & Co., Ltd., Osaka,
Japan), irinotecan SN-38 (CPT-11, Yakult Honsha Co., Ltd.,
Tokyo, Japan) [11] and methotrexate (MTX, Pfizer Japan
Inc., Tokyo, Japan) which are often used to treat
gynecological cancers [12]. They were dissolved in culture
medium and used immediately. For 3-(4,5-dimethyl-2-thia-
zolyl)-2,5-diphenyl-2H tetrazolium bromide (MTT) assay,
96-well micro well plates were set up in quadruplicate, each
well containing 5×103 cells in 100 μl medium. For continu-
ous drug exposure experiments, various diluted drugs in
50 μl were added after 48 h of incubation. The wells were
incubated for 72 h after the addition of drugs. MTT (50 μl
of 2 mg/ml; Wako Pure Chemical Industries) was added to
each well, and the plates were incubated for 4 h. The
medium was then removed, 150 μl of dimethyl sulfoxide
(DMSO, Sigma, St. Louis, MO, USA) was added to each
well, and the plates were agitated for 5 min. The optical
density was then read at 570 nm on a microplate reader
(Bio-Rad Laboratories, Hercules, CA, USA) and the effect-
ive concentration for 50 % kill was calculated from the dose
response curve (EC50: dose of drug required to reduce final
cell number or optical density in MTT assay to 50 % of
control) [13].
Mutational analysis
DNA was extracted from cultured cells using DNA extrac-
tion Kit (PureLink™ Genomic DNA Mini Kit, Invitrogen,
Life Technologies, Carlsbad, CA, USA). Somatic muta-
tions (substitutions, insertions or deletions) were assessed
using the Ion AmpliSeq™ Cancer Hotspot Panel v2, de-
signed to amplify 207 amplicons covering ~2800 COSMIC
mutations from the 50 most commonly reported onco-
genes and tumor suppressor genes: ABL1, AKT1, ALK,
APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1,
EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2,
FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS,
IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1,
MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA,
PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO,
SRC, STK11, TP53 and VHL (Ion Torrent, Life Technolo-
gies) [14, 15] (Additional file 1: Table S1).
Results
Histopathology of the culture specimen
Light microscopy revealed the original tumor to be clear
cell carcinoma, with a clear cytoplasm (Fig. 2a) and a
partial hobnail appearance (Fig. 2b).
Establishment of the cell line
After a 2-month stationary period, the fragments devel-
oped distinct out-growths. Initially, contamination of
spindle shaped fibroblasts was observed, but they disap-
peared from the cultures upon passaging the cells. The
HCH-1 cells grew well, without interruption, for more
than 230 months, and more than 50 serial passages were
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successively carried out. They continue to exhibit stable
growth.
Morphology of the cultured cells
The monolayer cultured cells appeared to be epithelial,
showing a pavement-like arrangement. Multilayering was
observed and confluency could not be achieved (Fig. 3).
The cells were polygonal and showed such neoplastic fea-
tures as bizarre aggregation of chromatin granules, thick-
ened nuclear membrane, and multiple large nucleoli.
Multinucleated giant cells were also seen (Fig. 4).
Growth characteristics
The growth curve was examined in passages 6 and 25 of
the HCH-1 cell line. Three days after culturing, the cells
grew logarithmically (Fig. 5). The population doubling
time, the saturation density, the plating efficiency and the
mitotic index were 66.4 h, 5.4×104 cells/cm2, 18.8 %, 2.7 %
in the 6th generation and 48.7 h, 8.2×104 cells/cm2, 12.9 %,
8.5 % in the 25th generation respectively.
Chromosomes
A modal chromosome number was in the hypodiploid
range (39–44) (Fig. 6). Chromosomal analysis showed the
following abnormalities; 40–42, X, der(X)t(X;1)(p22;q21-
23) [7], −1 [9], −4 [9], −5 [7], −8 [3], −9 [6], −10 [3], −11
[9],-12 [3], add (12)(p13) [7], −13 [9], −15 [9], −16 [9], −17
[5], −18 [7], add (18)(q23) [3], +19 [2], −19 [4], +20 [3],
−21 [4], −22 [3], +5-9mar (Fig. 7).
Fig. 2 Histology of the original tumor. The right ovarian tumor shows clear cell carcinoma, with a clear cytoplasm (a) and a partial hobnail appearance
(b), stained with hematoxylin and eosin (HE). (bar = 50 μm)
Fig. 3 Phase contrast microscopy. It reveals a pavement-like
arrangement. (bar = 100 μm)
Fig. 4 Cytopathology of cultured HCH-1 cells. Multinucleated giant
cells with spindle-shaped or multipolar cytoplasm were observed
with Papanicolaou stain. (bar = 50 μm)
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Heterotransplantation
Histopathologically, the transplanted tumors were clear
cell carcinoma i.e. with clear cytoplasm, closely resem-
bling the original tumor (Fig. 8). Electron microscopy re-
vealed that adjacent cells possessed desmosome-like
junctions (Fig. 9a). The cells had indented nuclei and
abundant mitochondria in the cytoplasm, and numerous
microvilli on the surfaces (Fig. 9b). These features sug-
gest that the cells were epithelial in origin.
Tumor markers
Positive levels were observed for: CA 125, 1400 U/ml; CA
19–9, 355 U/ml; and TPA, >1500 U/L. Negative markers
were: AFP, 1 ng/ml; CEA, 0.7 ng/ml; CA 72–4, 8.8 U/ml;
HCG, <1 mIU/ml; and SCC antigen, <0.5 ng/ml.
Immunohistochemical stainings
CA 125, CA 19–9, HNF-1β, and Annexin IV were dem-
onstrated immunohistochemically in cancer cells from
the original tumor and heterotransplanted tumors
(Figs. 10 and 11). Estrogen receptor and progesterone
receptor were not detected using immunocytochemistry.
Chemosensitivity
The EC50 values of anti-cancer drugs for HCH-1 cells
are listed in Table 1 (Additional file 2: Figure S1).
Fig. 5 Growth curves of HCH-1. (the 6th(●) and 25th(○) generations.)
Fig. 6 Distribution of chromosomal numbers in HCH-1 (6th generation). The modal number is in the hypo-diploid range
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Mutational analysis
The amount of 8.1 μg DNA was extracted from 2×106
cells. No variant was found in hotspot locations of 50
cancer genes but 12 of called variants outside of hotspot
locations were found (Table 2).
Discussion
Despite recent advances in cell culture it is still difficult to
establish a cell line, chiefly because of contamination with
fibroblasts. Fibroblasts usually grow faster than epithelial
cells and cause them to float. As fibroblasts are detached
faster than epithelial cells by trypsin, we removed every
fibroblast and most of the epithelial cells leaving a few
remaining epithelial colonies. These cells initially grew
slowly, but eventually grew well, and the first subculture
was made 2 months after the primary culture.
HCH-1 is a newly established cell line originating from
clear cell carcinoma of the ovary. To obtain convincing
evidence that HCH-1 is a strictly human ovarian clear
cell carcinoma cell line, we investigated its biological
characteristics and demonstrated the following:
1) The culture material was from a human clear cell
carcinoma of the ovary which was positive for HNF-1β
and Annexin IV.
2) HCH-1 has been kept viable in culture for over
230 months.
3) The cultured cells are neoplastic, show pleomorphism,
and pile up easily without contact inhibition.
4) The chromosomes show a human karyotype and
aneuploidy.
5) This line could be transplanted into SCID mice and
formed tumors histologically similar to the original
tumor.
Ovarian clear cell carcinoma cell lines have previously
been used for basic research, but only eleven (HUOCA-II
[16], RMG-I [17], OCC1 [18], RMG-II [19], OVISE [20],
OVTOKO [20], JHOC-5 [21], JHOC-6 [21], SMOV-2
[22], TAYA [23], RMG-V [24], TU-OC-1 [25]) have been
described in detail in the scientific literature (Table 3).
Each cell line originated from a tumor, metastatic tumor,
recurrent tumor, or ascites. The population doubling time
varied greatly (24–96 h), the modal chromosome numbers
were in the diploid range or more and all cells showed
karyotypical abnormalities. HCH-1 is the only cell line in
which the chromosome number is in the hypodiploid
Fig. 7 Karyotype of HCH-1 (6th generation). Chromosomal analysis showed various abnormalities
Fig. 8 Micrograph of a tumor transplanted into a SCID mouse. It
shows clear cell carcinoma closely resembling the original tumor.
(HE, bar = 50 μm)
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range. The hypodiploidy means the deletion of the chromo-
somes which are not necessarily important for cancer cells.
It will thus provide an additional and useful model system
for studying carcinogenesis.
Five cell lines are reported to express tumor markers, but
only two were positive immunohistologically. Tumor
markers are useful not only in diagnosing the ovarian can-
cer but also in detecting tumor recurrence and assessing
therapy. In our patient, CA125 and CA19-9 were useful
tumor markers because of their high serum levels preopera-
tively. HCH-1 is the second reported cell line of ovarian
clear cell carcinoma which produces both CA 125 and CA
Fig. 9 Electron micrograph of a tumor transplanted into a SCID mouse. The cells were attached via desmosome junctions (a) (bar = 4 μm), had
indented nuclei in the cytoplasm and numerous microvilli on the surfaces (b) (bar = 1 μm)
Fig. 10 Immunohistochemical stainings of the original tumor (a, c) and heterotransplanted tumor (b, d) with CA 125 (a, b) and CA 19–9 (c, d).
Cancer cells were positive for CA 125 and CA 19–9 (a, b, c, d; bar = 100 μm)
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19–9 markers. Therefore it will provide a useful, additional
tool in studies of those ovarian cancers that produce tumor
markers.
The ovary is a target organ for steroid hormones, but
the cell lines OVISE, OVTOKO and HCH-1 do not pos-
sess estrogen or progesterone receptors as judged by
immunohistochemical staining. Because the action,
mechanism and localization of steroid hormone recep-
tors are still relatively poorly understood, HCH-1 can be
used as an additional negative control in hormone re-
ceptor studies.
Chemotherapy is an important adjunct to surgery in the
treatment of ovarian cancer. The CAP (CPA, ADM, CDDP)
regimen had, until recently, been used for ovarian epithelial
carcinoma, but has now been largely superseded by a regi-
men of paclitaxel and carboplatin. CPT-11 has also been
used for clear cell carcinoma and recurrent tumors [26].
However, these management strategies are not always
effective.
The MTT assay is considered a rapid and accurate
method of screening for drug responsiveness of cultured
cells and so was selected for our chemosensitivity test-
ing. In vitro sensitivity was defined as more than 50 %
growth inhibition at peak plasma concentrations. Ac-
cording to this criterion, HCH-1 cells are sensitive to
ACD, CBDCA, CDDP and MMC. These results do not,
however, reflect our patient’s clinical course, suggesting
that these drugs were metabolized before they could
Fig. 11 Immunohistochemical stainings of the original tumor (a, c) and heterotransplanted tumor (b, d) with HNF-1β (a, b) and Annexin IV (c, d).
Cancer cells were positive for HNF-1β and Annexin IV (a, b, c, d; bar = 100 μm)
Table 1 Chemosensitivity using a 3-(4,5-dimethylthiazol-2-yl)-2,5-

















EC50, effective concentration for 50 % kill; PPC, peak plasma concentration
taken intravenously; ACD actinomycin D, ADM doxorubicin, BLM bleomycin,
CBDCA carboplatin, CDDP cisplatin, CPA 4-hydroperoxy-cyclophosphamide,
CPT-11 irinotecan hydrochloride, 5-FU 5-fluorouracil, MMC mitomycin C, MTX
methotrexate, PTX paclitaxel, VCR vincristine, VLB vinblastine, VP-16 etoposide
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Table 2 Variants outside of hotspot locations of 50 cancer genes
Chromosome Position Ref Allele Variant Allele Type Frequency Variant Type Allele Sourcea Gene Symbol Coverage AA Ref AA Variant
1 chr3 178917005 A G Heterozygous 40.2 SNP Novel PIK3CA 1950 unknown unknown
2 chr4 1807894 G A Homozygous 100 SNP Novel FGFR3 1222 T T
3 chr4 55141055 A G Homozygous 100 SNP Novel PDGFRA 1755 I I
4 chr4 55972974 T A Homozygous 100 SNP Novel KDR 1987 Q H
5 chr4 153249443 C T Homozygous 100 SNP Novel FBXW7 1998 V V
6 chr5 112175770 G A Homozygous 100 SNP Novel APC 1981 A A
7 chr5 149433596 TG GA Heterozygous 32.1 MNP Novel CSF1R 1993 unknown unknown
8 chr7 55249063 G A Heterozygous 52.1 SNP Novel EGFR 1999 Q Q
9 chr13 28610183 A G Homozygous 100 SNP Novel FLT3 1999 unknown unknown
10 chr17 7579472 G C Heterozygous 49.2 SNP Novel TP53 1976 P R
11 chr19 1220321 T C Heterozygous 55.4 SNP Novel STK11 1894 unknown unknown
12 chr20 57484611 G A Heterozygous 48.9 SNP Novel GNAS 1994 R H
Ref reference, AA amino Acid













exert their effect. The MTT assay may provide a poten-
tially useful approach for evaluating individual chemo-
sensitivity profile but new principle for chemosensitivity
testing, in vivo or genomic testing, would be expected.
Recently numerous genetic alterations revealed in ovarian
cancer. The PIK3CA [3] gene was found to be specifically
mutated in ovarian clear cell carcinoma. Then ARID1A [4]
mutation and the consequent loss of expression are fre-
quently observed. As a molecular study, somatic mutations
were assessed using Panels of 50 most commonly reported
oncogene and tumor suppressor genes. HCH-1 had no
variant in hotspot locations of 50 genes including KRAS,
PIK3CA, PTEN and TP53, but 12 of called variants outside
of hotspot locations, those roles have not been known well.
Important roles of carcinogenesis might be found in these
variants or another cancer genes. Unfortunately, ARID1A
was not included in this Panel.
Conclusions
Since it is impossible to establish a cell line from the ma-
lignant tumor of each patient, the cell line that we estab-
lished, characterized and report in this paper may be
very useful in basic research on ovarian cancer, though
the results of these analyses could not necessarily apply
to new practical use. We have much to learn about the
pathogenesis of clear cell carcinoma and this extra line
of enquiry may lead us to a better understanding of how
to treat and cure this serious disease.
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